These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 28644904)

  • 1. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
    Hjalte F; Carlsson KS; Schmitt-Egenolf M
    Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Dermatology; 2012; 225(4):326-32. PubMed ID: 23328678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
    Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
    J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2012 Apr; 166(4):797-802. PubMed ID: 22182212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
    Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
    BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis.
    Iskandar IYK; Ashcroft DM; Warren RB; Lunt M; McElhone K; Smith CH; Reynolds NJ; Griffiths CEM
    Br J Dermatol; 2017 Nov; 177(5):1410-1421. PubMed ID: 28369707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
    Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in patients with generalized pustular psoriasis - a Swedish register study.
    Norlin JM; Löfvendahl S; Schmitt-Egenolf M
    Ann Med; 2024 Dec; 56(1):2341252. PubMed ID: 38738413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
    Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
    Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients with palmoplantar pustulosis - a Swedish register study.
    Norlin JM; Löfvendahl S; Schmitt-Egenolf M
    Ann Med; 2024 Dec; 56(1):2386524. PubMed ID: 39115530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary.
    Herédi E; Rencz F; Balogh O; Gulácsi L; Herszényi K; Holló P; Jókai H; Kárpáti S; Péntek M; Remenyik É; Szegedi A; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1():S111-9. PubMed ID: 24832842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.